FDA cleared niche Alpha-Stim offers FDA-cleared non-invasive brain stimulation for anxiety, insomnia, and pain, highlighting a defensible clinical niche that can be leveraged to target healthcare providers, clinics, and veterans' services seeking non-pharmacological options.

Military veteran focus Partnerships emphasizing veteran access, such as the AcuityMD collaboration, present a clear entry point with military healthcare programs, VA networks, and veteran service organizations as potential high-value customers.

Cost advantage The technology is positioned as faster and more cost-effective over time compared to prescription drugs, suggesting opportunities to approach payers, patient access programs, and formulary discussions emphasizing long-term savings.

Strategic acquisitions EPI’s history of acquisitions like Pulvinar Neuro signals a growth trajectory and potential for integrated neuromodulation solutions, opening doors to partnerships with research institutions and more advanced device ecosystems.

Digital ecosystem Current tech stack with Google Ads, LinkedIn, WordPress, and e-commerce platforms indicates readiness for targeted digital outreach, direct-to-clinic promotions, and online education campaigns to expand user adoption.